Chloroquine-resistant Plasmodium vivax in Papua New Guinea

Trans R Soc Trop Med Hyg. Mar-Apr 1992;86(2):121-2. doi: 10.1016/0035-9203(92)90531-g.


An Australian expatriate on regular weekly antimalarial prophylaxis with chloroquine base and Maloprim developed symptomatic Plasmodium vivax infection which failed to respond adequately to 600 mg of chloroquine base. More ominously, a resident of the Highlands region of Papua New Guinea contracted vivax malaria which failed to be cleared by 2400 mg chloroquine base administered over 4 d. Both patients had achieved appropriate blood and plasma concentrations of chloroquine after treatment. Chloroquine-resistant P. vivax is now a clinical fact in Papua New Guinea.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Antimalarials / therapeutic use
  • Chloroquine / therapeutic use*
  • Dapsone / therapeutic use
  • Drug Combinations
  • Drug Resistance
  • Humans
  • Malaria, Vivax / drug therapy*
  • Male
  • Papua New Guinea
  • Plasmodium vivax / drug effects
  • Pyrimethamine / therapeutic use
  • Sulfadoxine / therapeutic use


  • Antimalarials
  • Drug Combinations
  • fanasil, pyrimethamine drug combination
  • Maloprim
  • Sulfadoxine
  • Chloroquine
  • Dapsone
  • Pyrimethamine